1
                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                 SCHEDULE 13D/A5

                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

NAME OF ISSUER:  AMARILLO BIOSCIENCES, INC. (the "Company")

TITLE OF CLASS OF SECURITIES:  Common Stock, par value $.01 per share

CUSIP NUMBER:  02301P106

NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICES AND
COMMUNICATIONS: EDWARD L. MORRIS, SPROUSE, SMITH & ROWLEY, P.C., P. O. Box
15008, Amarillo, Texas 79105; 806/368-3311.

DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: February 11, 2000

         If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box. [ ]

         Note. Schedules filed in paper format shall include a signed original
         and five copies of the schedule, including all exhibits. See Rule
         13d-7(b) for other parties to whom copies are to be sent.

         * The remainder of this cover page shall be filled out for a reporting
         person's initial filing on this form with respect to the subject class
         of securities, and for any subsequent amendment containing information
         which would alter disclosures provided in a prior cover page.

         The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).


                                       1
   2
CUSIP No. 02301P106

1.       NAME OF REPORTING PERSON: Hayashibara Biochemical Laboratories, Inc.
         ("HBL")

2.       CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
         (a)                                                             [ ]
         (b)                                                             [ ]

3.       SEC USE ONLY:

4.       SOURCE OF FUNDS:  CO

5.       CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
         TO ITEMS 2(d) OR 2(e):                                          [ ]

6.       CITIZENSHIP OR PLACE OF ORGANIZATION:  Japan

7.       SOLE VOTING POWER: 3,290,781 shares

8.       SHARED VOTING POWER:

9.       SOLE DISPOSITIVE POWER: 3,290,781 shares

10.      SHARED DISPOSITIVE POWER:

11.      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
         3,290,781 shares

12.      CHECK BOX IF THE AGGREGATE AMOUNT IN RIGHT-OF-WAY (11) EXCLUDES
         CERTAIN SHARES (SEE INSTRUCTIONS):                              [ ]

13.      PERCENT OF CLASS REPRESENTED BY AMOUNT IN RIGHT-OF-WAY (11): 44%

14.      TYPE OF REPORTING PERSON:  CO


                                       2
   3

Item 6 CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER:

         On September 30, 1999, the Company entered into an Agreement to Convert
         Debt ("Agreement") with HBL. On October 15, 1999, pursuant to this
         Agreement, the Company issued 1,111,831 shares of its common stock to
         HBL in exchange for the release of $1,005,486.30 in debt and accrued
         interest.

         The Agreement called for an exchange to take place on November 30,
         1999, in which HBL would contribute $1,000,000 to the Company and
         receive an equivalent amount of the Company's common stock. By mutual
         consent, the Company and HBL agreed that the November 30, 1999
         transaction called for under the Agreement will not take place.
         Instead, HBL loaned $1,000,000 to the Company at an interest rate of 4
         1/2%, compounded annually.

         The Agreement also called for an exchange to take place on February 29,
         2000, in which HBL would contribute $1,000,000 to the Company and
         receive an equivalent amount of the Company's common stock. By mutual
         consent, the Company and HBL have agreed that the February 29, 2000
         transaction called for under the Agreement would not take place.
         Instead, HBL has agreed to loan $1,000,000 to the Company at an
         interest rate of 4 1/2%, compounded annually. This mutual consent
         discharges all remaining obligations of ABI and HBL under the
         Agreement.

                                   SIGNATURES

                  After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.

                  Dated: March 8, 2000.

                                    HAYASHIBARA BIOCHEMICAL LABORATORY, INC.


                                    By: /s/ KEN HAYASHIBARA
                                        -----------------------------------
                                            KEN HAYASHIBARA, President


                                       3